A laboratory-focused comparison of Retatrutide (LY3437943) and Semaglutide — triple receptor agonist versus single GLP-1 receptor agonist. Receptor profile, mechanism, class and analytical release for UK researchers.
Triple receptor agonist targeting GLP-1, GIP and glucagon — the newest generation of incretin research peptides.
Shop Retatrutide →
The established single GLP-1 receptor agonist reference peptide, used across metabolic and glycaemic research models.
Shop Semaglutide →| Feature | Retatrutide | Semaglutide |
|---|---|---|
| Receptor profile | GLP-1 · GIP · Glucagon | GLP-1 only |
| Compound class | Triple agonist peptide | Single-receptor GLP-1 agonist |
| Primary research interest | Triple-hormone synergism, energy expenditure, body composition | GLP-1 pathway biology and glycaemic research |
| Analytical release | ≥99% HPLC-UV, mass spec, endotoxin | ≥99% HPLC-UV, mass spec, endotoxin |
| Form | Lyophilised powder | Lyophilised powder |
| Storage | 2–8°C dark; ~30 days reconstituted | 2–8°C dark; ~30 days reconstituted |
| Research maturity | Emerging triple-incretin reference | Established single-GLP-1 reference |
Semaglutide is the anchor GLP-1 reference in modern peptide research — a well-characterised single-receptor agonist against which every newer incretin candidate is measured. Retatrutide sits at the opposite end of the class spectrum: three receptor targets in a single molecule, adding GIP and glucagon activity to the GLP-1 axis.
For laboratory groups isolating the contribution of GLP-1 alone versus combined incretin signalling, the two compounds are the natural comparators. The paired middle-ground compound — tirzepatide (dual GLP-1 / GIP) — is covered in our companion Retatrutide vs Tirzepatide guide.
All observations here are laboratory research context. BuyRetaUK does not make clinical, therapeutic or off-label claims.
Retatrutide activates three receptors (GLP-1, GIP and glucagon). Semaglutide activates one (GLP-1). Retatrutide is used where research questions require combined incretin activity; semaglutide is the isolated GLP-1 reference.
Yes — both are engineered as long-acting peptides suitable for weekly-cadence research protocols in the studies that reference them.
Comparative research designs frequently include both to attribute observed effects to GLP-1 alone versus combined GLP-1 / GIP / glucagon activity. Sourcing both from matched release specifications supports that comparison.
Yes — every batch of both compounds ships with a batch-specific Certificate of Analysis reporting HPLC purity, mass-spec identity and endotoxin data.
No. BuyRetaUK supplies both strictly for in-vitro laboratory research. Neither is offered by BuyRetaUK for human or veterinary administration.
Peer-reviewed citations are added as each article is expanded. See our editorial standards for our sourcing and accuracy commitments.
The BuyRetaUK editorial team publishes laboratory-focused reference content on research peptides, analytical methods and Certificates of Analysis. All articles are written for in-vitro research contexts only.
View profile →Every editorial article is reviewed against our accuracy commitment and quality-assurance checklist before publication. Named reviewer profiles are added as our reviewer network expands.
View profile →Every article follows a documented editorial process — sourcing, scientific review, update cadence and correction policy — so researchers can rely on what we publish.
Read the full editorial standards →Baseline understanding of the triple agonist.
Triple vs dual receptor profile.
Triple vs single GLP-1 profile.
Verify identity and purity of any compound.
All GLP-1 / GIP / glucagon research peptides.
A laboratory overview of retatrutide (LY3437943) — a triple agonist research peptide acting on the GLP-1, GIP and glucagon receptors.
6 min read →Product ComparisonsSide-by-side comparison of retatrutide and tirzepatide across receptor profile, research context and analytical considerations.
5 min read →Purity & Laboratory TestingThe quality standards BuyRetaUK applies to every batch — sourcing, analytical testing, storage and traceability.
5 min read →RetatrutideBackground on retatrutide in the academic literature — receptor pharmacology, study context and analytical handling.
8 min read →Triple vs dual incretin agonist — receptor profile and research framing.
View comparison →Side by sideSelective GLP-1 agonist vs dual GIP/GLP-1 agonist — receptor pharmacology and evidence comparison.
View comparison →Multi-compoundAll GLP-1 / GIP / glucagon research compounds in one place.
View comparison →The UK commercial hub for research-grade Retatrutide — lab data, COAs and dispatch.
Browse collection →CollectionThe full retatrutide range with research context and lab data.
Browse collection →CollectionResearch guides, comparisons and laboratory reference material.
Browse collection →Every batch of Retatrutide, Semaglutide ships with a third-party HPLC and mass-spec Certificate of Analysis. Browse the live COA library to verify your lot.
Retatrutide is the more recently characterised compound in the academic literature, while tirzepatide is the more established reference.
Read: Retatrutide vs Tirzepatide →Yes — both act on the GLP-1 receptor, but retatrutide also acts on GIP and glucagon receptors.
Read: Retatrutide vs Semaglutide →No. Retatrutide is supplied strictly for laboratory research and is not approved for human or veterinary administration.
Read: What is Retatrutide? →In published research it has been characterised as a triple agonist acting on the GLP-1, GIP and glucagon receptors.
Read: What is Retatrutide? →Side-by-side comparison of retatrutide and tirzepatide across receptor profile, research context and analytical considerations.
5 min read — Read guide →